Results from a Phase 1/2 trial of BB2603, a terbinafine‐based topical nano‐formulation, in onychomycosis and tinea pedis
Sign Up to like & getrecommendations! Published in 2022 at "Mycoses"
DOI: 10.1111/myc.13448
Abstract: BB2603 is a nano‐formulation of the antifungal drug terbinafine with the polymer polyhexamethylene biguanide (PHMB) as an excipient to enhance solubility and drug delivery to skin and nails. BB2603 is delivered topically using a low‐velocity… read more here.
Keywords: onychomycosis tinea; tinea pedis; terbinafine; bb2603 ... See more keywords